Gilead Sciences and GlaxoSmithKline will both reveal clinical test trial results for HIV treatment at an upcoming HIV/AIDS conference.
GSK’s drug, Dolutegravir, was approved by the FDA to treat HIV infection. However, it has been speculated that Gilead’s drug Bictegravir may have greater potency and less side effects than Dolutegravir.
Bictegravir is at the end of Phase 3 trials so the conference will focus on a Phase 2 trial study.
Presentations will take place this week at the Conference on Retroviruses and Opportunistic Infections in Seattle, Washington.
Read the Market Exclusive article